Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Target therapy has improved the outcome of neuroendocrine tumors (NETs), but little is known about the strategies to overcome the acquired resistance. MET is considered one of the putative mechanisms of resistance. RET is also rearranged in some other endocrine tumors (like thyroid).
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Cella C, Barberis M, Spad F, Pisa E, Laffi A,
Keywords: Everolimus, MET, RET,
Introduction: Everolimus has been studied in preclinical and clinical settings, showing it to be active and effective. Tumors exhibiting the constitutively activated phosphatidylinositol-3-kinase-AKT-mTOR (PI3K/AKT/mTOR) pathway, are potentially susceptible to mTOR inhibitors. Even though Everolimus is both an antiproliferative and anti-angiogenic drug, we do not know the possible prognostic or predictive role of p-mTOR pathway.
Conference: 9th Annual ENETSConcerence (2012)
Presenting Author:
Authors: Spada F, Pisa E, Lorizzo K, Barberis M, Fazio N,
Keywords: mTOR,
Introduction: Conventional chemotherapy has not yet a well defined role in well/moderately differentiated (WD) neuroendocrine carcinomas (NECs).
Conference:
Presenting Author:
Authors: SPADA F, SCARABELLI L, LORIZZO K, PELOSI G, BARBERIS M,
Keywords: neuroendocrine, ERCC1, Ki 67 ,
Introduction: In MEN1, the main risk factor of metastases is pancreatic tumor size. We and others recommend limiting surgery to pancreatic tumors >20 mm or growing based on their size measured with EUS.
Conference: 8th Annual ENETSConcerence (2011)
Presenting Author:
Authors: Barbe C, Murat A, Dupas B, Ruszniewski P, Tabarin A,
Keywords: MEN 1, pancreas, endoscopic ultrasonography, magnetic resonance imaging, metastases,